Results 231 to 240 of about 742,291 (286)

Warburg redefined: Metabolites, mitochondria and macrophages in immune regulation

The Journal of Physiology, EarlyView.
Abstract figure legend Following pro‐inflammatory stimulation, macrophages undergo Warburg‐like metabolic rewiring that extends more than increased glycolysis. The non‐canonical functions of glycolytic enzymes and lactate accumulation control macrophage immune responses through multiple signalling pathways (a).
Yukun Min, Órlaith C. Henry, Luke A. J. O'Neill   +2 more
wiley   +1 more source

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. [PDF]

Proc Natl Acad Sci U S A
Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, Lu F, Ahmed B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, D'Andrea AD, Qiu X, Brown M.   +15 more
europepmc   +1 more source

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. [PDF]

Curr Treat Options Oncol
Weiner-Gorzel K, McSorley L, Walshe JM.
europepmc   +1 more source

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. [PDF]

Clin Pharmacokinet
Torrent-Rodríguez A, Bastida C, Martín ECS, Escartín IM, Puszkiel A, Blanchet B, Laguna JC, Gorria T, Montes A, Macías I, Alvárez A, Arance A, Moreno FA, Fabregat-Bolufer AB, Soler E, Muner DS.   +15 more
europepmc   +1 more source

Cumulative cytotoxic chemotherapy exposure after the introduction of PARP inhibitors in advanced high-grade serous tubo-ovarian and primary peritoneal carcinoma: A descriptive single-center historical cohort study. [PDF]

Mol Clin Oncol
Osawa N, Chikazawa K, Imai K, Shimizu A, Ko H, Kuwata T.   +5 more
europepmc   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape. [PDF]

Cancer Med
Chen Y, Cao J, Huang R, Lou J, Gu J, Luo Z, Yao T, Xie J.   +7 more
europepmc   +1 more source

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them

International Journal of Molecular Sciences, 2022
PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer ...
Dongha Kim, Hye Jin Nam
exaly   +2 more sources

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

Cancers, 2020
Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation ...
Seock-Ah Im
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The Vasoactivity of PARP Inhibitors

2015
PARP-inhibition has proven to be an attractive therapeutic approach in cancer whereby the effectiveness of DNA-damaging therapy can be enhanced by inhibiting the PARP-mediated DNA-repair process. Generally there is good concordance between enhanced therapeutic efficacy in vitro and that observed in vivo.
Williams, Kaye J., McCrudden, Cian M.
openaire   +2 more sources

PARP Inhibitors

Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire   +2 more sources